Former SAC Capital Advisors fund manager Mathew Martoma’s securities fraud convictions should stand and he shouldn’t get a new trial for the most lucrative insider-trading scheme ever, U.S. prosecutors said.
Mathew Martoma, the former SAC Capital Advisors trader convicted of insider trading in February, can no longer say he has a degree from Stanford Graduate School of Business.
Former SAC Capital Advisors portfolio manager Mathew Martoma asked a U.S. judge to throw out his insider trading conviction, saying federal prosecutors did not prove he committed a crime and that improper evidence and jury bias tainted the verdict.
Former federal prosecutor Doug Burns on the future of SAC Capital after Mathew Martoma’s guilty verdict.
Former SAC Capital Advisors fund manager Mathew Martoma was portrayed by his lawyer as the victim of a 'rush to judgement' by prosecutors looking to use him to bring insider-trading charges against his former boss, Steven A. Cohen.
The judge in Mathew Martoma’s insider-trading trial warned his lawyers against questions tied to Steven Cohen’s trading strategies, saying it could open the case to a wider probe of the SAC Capital Advisors founder.
Mathew Martoma's insider trading trial took a surprising turn Thursday afternoon.
Sidney Gilman, the 81-year-old former University of Michigan neurologist who claims he passed tips about clinical tests of an Alzheimer’s drug to SAC Capital Advisors fund manager Mathew Martoma, said he has 'holes' in his memory of a key meeting.
The prosecution’s star witness against Mathew Martoma testified that he lied about passing inside information to the former SAC Capital Advisors fund manager when he was first questioned by agents of the Federal Bureau of Investigation in September 2011.
A doctor who supervised testing of an Alzheimer’s disease drug said he was 'flabbergasted' and 'shocked' at the precise information that former SAC Capital Advisors fund manager Mathew Martoma had about the drug trial results.